Waters Corporation
WAT Healthcare Medical - Diagnostics & Research NYSE
$302.54
$-13.05 (-4.14%)
Open: $311.65 | High: $314.14 | Low: $302.44 | Prev Close: $315.59
Market Cap: $18.00B
Volume: 995K | Avg: 965K
Last updated: March 09, 2026 at 02:05 AMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 492
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 28.12 |
| P/B Ratio | 7.03 |
| P/S Ratio | 5.69 |
| EPS | $10.76 |
| Beta | 1.20 |
| Shares Outstanding | 59.51M |
| 52-Week High | $414.15 |
| 52-Week Low | $275.05 |
| SMA 50 | $362.66 |
| SMA 200 | $342.30 |
| Next Earnings | May 05, 2026 01:30 PM ET |
Financial Ratios
| Gross Margin | 58.9% |
| Operating Margin | 26.6% |
| Net Margin | 20.3% |
| ROE | 28.5% |
| ROA | 12.6% |
| Debt/Equity | 0.55 |
| Current Ratio | 0.00 |
| Quick Ratio | 0.00 |
Balance Sheet
| Total Assets | $5.08B |
| Total Liabilities | $2.52B |
| Total Equity | $2.56B |
|
|
|
| Cash | $587.83M |
| Total Debt | $1.41B |
| Net Debt | $819.61M |
Income Statement
| Revenue | $3.17B |
| Gross Profit | $1.83B |
| Operating Income | $893.22M |
| Net Income | $642.63M |
|
|
|
| EBITDA | $1.01B |
| Revenue/Share | $53.16 |
Cash Flow
| Operating CF | $652.55M |
| CapEx | $112.75M |
| Free Cash Flow | $539.81M |
|
|
|
| Book Value/Share | $43.01 |
| Tangible Book/Share | $11.13 |
| Equity/Share | $43.01 |
Technical Indicators
| RSI (14) | 40.65 Neutral |
| MACD |
-14.79
Signal: -15.44
|
| Volatility | 47.79% |
| Trading Signal | Bullish |
Performance & Returns
| 1 Year | -15.62% |
| Sharpe Ratio | -0.53 Poor |
| Volatility (Ann.) | 35.95% Moderate |
| WAT (1Y) | -15.62% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | -28.65% |
Sector Comparison (Healthcare)
| Metric | WAT | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 28.12 | 27.65 | 57% |
| P/B Ratio | 7.03 | -19.66 | 81% |
| ROE (%) | 28.52% | -9.83% | 77% |
| Net Margin (%) | 20.30% | 9.11% | 77% |
| Stock Score | 492 | 544.0 | 19% |
| 1Y Return (%) | -15.62 % | +8.61 % | 19% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WAT | $302.54 | $311.98 | $314.34 | $319.55 | $362.17 | $342.18 | 40.65 | -14.79 | 47.79% | 249318 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the WAT stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| WAT | Letting Home Sellers Test the Waters Before Listing Could Boost Housing Supply as Much as 12% | Neutral | businesswire.com | Read More |
| WAT | Waters (WAT) Down 8.4% Since Last Earnings Report: Can It Rebound? | Neutral | zacks.com | Read More |
| WAT | Waters Flagship ARES‑G3 Rheometer Sets New Benchmark for Data Quality at Breakthrough Speed | Neutral | prnewswire.com | Read More |
| WAT | Waters (WAT) Upgraded to Buy: What Does It Mean for the Stock? | Neutral | zacks.com | Read More |
| WAT | Waters Corporation (WAT) Presents at TD Cowen 46th Annual Health Care Conference Transcript | Neutral | seekingalpha.com | Read More |
Recent Insider Trading
No recent insider trading data available for WAT
Company Information
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by life science, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
| CEO | Udit Batra |
| Employees | 7600 |
| Country | US |
| IPO Date | 1995-11-17 |
| Exchange | NYSE |
| Website | https://www.waters.com |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
Similar Stocks (Healthcare - Medical - Diagnostics & Research)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category